Active Ingredient(s): Ertugliflozin
FDA Approved: * December 19, 2017
Pharm Company: * MERCK SHARP DOHME
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Steglatro Overview

Ertugliflozin, sold under the brand name Steglatro, is a medication for the treatment of type 2 diabetes.[2][3] The most common side effects include fungal infections of the vagina and other infections of the female reproductive system.[3] Ertugliflozin is a sodium/glucose cotransporter 2 (SGLT2) inhibitor[2][3] and is in the class of drugs known as gliflozins.[medical citation needed] In the Unite...

Read more Steglatro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Steglatro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 15mg, 5mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Steglatro: (2 results)

Sorted by National Drug Code
  • 0006-5363 Steglatro 5 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.
  • 0006-5364 Steglatro 15 mg Oral Tablet, Film Coated by Merck Sharp & Dohme Corp.

Other drugs which contain Ertugliflozin or a similar ingredient: (5 results)